Can you believe this is our 100th episode??? It has been a little over 6 months since our official launch and we are now running full steam, thanks to a hardworking team. Cheers to the members of AMiNDR, and cheers to you for listening to us. This episode is for those of you who are interested in what’s already on the marker for treating Alzheimer’s disease. That’s right, you have knowingly or by chance stumbled upon our episode on refining or repurposing existing medications, as well as improving methods of drug delivery. You will hear about advances in refining the use of Memantine, Donepezil, and Rivastigmine, and exploring the potential of drugs like Lithium, Escitalopram, or Sildenafil to alleviate the symptoms of AD. We also cover papers that look at refining methods of drug delivery, efficiency, or bioavailability. Sections in this episode: Section 1: Refining existing drugs 3.53 Memantine (1 paper): 4.26 Donepezil (3 papers): 6.03 Rivastigmine (1 paper): 12.55 Section 2: Refining methods (delivery, efficiency, bioavailability): (5 papers) 15.25 Section 3: Repurposing approved drugs (6 papers): 28.26 Bonus paper: 43.29
Can you believe this is our 100th episode??? It has been a little over 6 months since our official launch and we are now running full steam, thanks to a hardworking team. Cheers to the members of AMiNDR, and cheers to you for listening to us.
This episode is for those of you who are interested in what’s already on the marker for treating Alzheimer’s diseases. That’s right, you have knowingly or by chance stumbled upon our episode on refining or repurposing existing medications, as well as improving methods of drug delivery. You will hear about advances in refining the use of Memantine, Donepezil, and Rivastigmine, and exploring the potential of drugs like Lithium, Escitalopram, or Sildenafil to alleviate the symptoms of AD. We also cover papers that look at refining methods of drug delivery, efficiency, or bioavailability.
Sections in this episode:
Section 1: Refining existing drugs 3.53
Memantine (1 paper): 4.26
Donepezil (3 papers): 6.03
Rivastigmine (1 paper): 12.55
Section 2: Refining methods (delivery, efficiency, bioavailability): (5 papers) 15.25
Section 3: Repurposing approved drugs (6 papers): 28.26
Bonus paper: 43.29
------------------------------------------------------------------
To receive the list of papers covered, please fill this form:
--------> https://forms.gle/CVVbznAFM8pamdgk6 -------
or by tweeting at us: @AMiNDR_podcast
------------------------------------------------------------------
We would appreciate your feedback so we can better cater to your needs.
You can fill our feedback form here
----------> https://forms.gle/5aq2JyrT6g4P1m8v6
You can also share your thoughts and suggestions by contacting us:
Email: amindrpodcast@gmail.com
Facebook: AMiNDR
Twitter: @AMiNDR_podcast
Instagram: @AMiNDR.podcast
------------------------------------------------------------------
Today's episode was scripted by Sarah Louadi and Naila Kuhlmann, reviewed by Joseph Liang, and hosted and edited by Sarah Louadi. All of this was made possible thanks to an entire team of volunteers behind the scenes.
Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic.
https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w
------------------------------------------------------------------
If you are interested in joining the team, send us your CV by email. We are specifically looking for help with abstract summary and podcast editing. However, if you are interested in helping in other ways, don't hesitate to apply anyways.
------------------------------------------------------------------
*About AMiNDR: *
Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!"